Identification of biomarkers for apoptosis in cancer cell lines using metabolomics: Tools for individualized medicine

Journal of Internal Medicine

Volumn 274, Issue 5, 2013, Pages 425-439

  Halama, A ^a   Riesen, N ^a   Moller G ^a   Hrabe de Angelis M ^a,b,c   Adamski, J ^a,b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

Apoptosis; Biomarkers; Cancer; Mass spectrometry; Metabolomics

Indexed keywords

ACYLCARNITINE; ALANINE; AMINO ACID; CAMPTOTHECIN; CASPASE 3; CASPASE 7; CHOLINE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLUTAMIC ACID; GLUTATHIONE; STAUROSPORINE; TAURINE;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL CULTURE; CELL DEATH; CELL STRAIN HEK293; CELL VIABILITY; CONCENTRATION (PARAMETERS); GENETIC ASSOCIATION; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MEASUREMENT; METABOLOMICS; NEWBORN SCREENING; OVARY CARCINOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; TANDEM MASS SPECTROMETRY; UPREGULATION;

APOPTOSIS; BIOMARKERS; CANCER; MASS SPECTROMETRY; METABOLOMICS;

ALANINE; AMINO ACIDS; APOPTOSIS; BIOLOGICAL MARKERS; CARNITINE; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; ETOPOSIDE; FLOW INJECTION ANALYSIS; FLUOROURACIL; GLUTAMIC ACID; HEK293 CELLS; HEP G2 CELLS; HUMANS; INDIVIDUALIZED MEDICINE; METABOLOMICS;

EID: 84885698144     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12117     Document Type: Review

References (104)

1. Wolkenhauer O, Auffray C, Baltrusch S et al. Systems biologists seek fuller integration of systems biology approaches in new cancer research programs. Cancer Res 2010; 70: 12-13.
2. Tomita M, Kami K. Cancer. Systems biology, metabolomics, and cancer metabolism. Science 2012; 336: 990-1.
3. Tweeddale H, Notley-McRobb L, Ferenci T. Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool ("metabolome") analysis. J Bacteriol 1998; 180: 5109-16.
4. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29: 1181-9.
5. Fiehn O. Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks. Comp Funct Genomics 2001; 2: 155-68.
6. Gieger C, Geistlinger L, Altmaier E et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet 2008; 4: e1000282.
7. Shackleton C. Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis. J Steroid Biochem Mol Biol 2010; 121: 481-90.
8. Psychogios N, Hau DD, Peng J et al. The human serum metabolome. PLoS ONE 2011; 6: e16957.
9. Hyotylainen T. Novel methodologies in metabolic profiling with a focus on molecular diagnostic applications. Expert Rev Mol Diagn 2012; 12: 527-38.
10. Vizán P, Mazurek S, Cascante M. Robust metabolic adaptation underlying tumor progression. Metabolomics 2008; 4: 1-12.
11. Fiehn O, Barupal DK, Kind T. Extending biochemical databases by metabolomic surveys. J Biol Chem 2011; 286: 23637-43.
12. Suhre K, Shin SY, Petersen AK et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011; 477: 54-60.
13. Ceglarek U, Shackleton C, Stanczyk FZ, Adamski J. Steroid profiling and analytics: going towards sterome. J Steroid Biochem Mol Biol 2010; 121: 479-80.
14. Shriver Z, Raguram S, Sasisekharan R. Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Discov 2004; 3: 863-73.
15. Oresic M. Metabolomics, a novel tool for studies of nutrition, metabolism and lipid dysfunction. Nutr Metab Cardiovasc Dis 2009; 19: 816-24.
16. Griffiths WJ, Wang Y. Mass spectrometry: from proteomics to metabolomics and lipidomics. Chem Soc Rev 2009; 38: 1882-96.
17. Artati A, Prehn C, Möller G, Adamski J. Assay tools for metabolomics. Suhre K, ed. Genetics Meets Metabolomics: From Experiment to Systems Biology. New York: Springer, 2012; 13-38.
18. Suhre K, Gieger C. Genetic variation in metabolic phenotypes: study designs and applications. Nat Rev Mol Cell Biol 2012; 13: 1-11.
19. Zivkovic AM, Wiest MM, Nguyen UT, Davis R, Watkins SM, German JB. Effects of sample handling and storage on quantitative lipid analysis in human serum. Metabolomics 2009; 5: 507-16.
20. Römisch-Margl W, Prehn C, Bogumil R, Röhring C, Suhre K, Adamski J. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics 2012; 8: 133-42.
21. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012; 58: 139-47.
22. Dunn WB, Ellis DI. Metabolomics: current analytical platforms and methodologies. Trends Anal Chem 2004; 24: 285-94.
23. Koal T, Deigner HP. Challenges in mass spectrometry based targeted metabolomics. Curr Mol Med 2010; 10: 216-26.
24. Griffiths WJ, Koal T, Wang Y, Kohl M, Enot DP, Deigner HP. Targeted metabolomics for biomarker discovery. Angew Chem Int Ed Engl 2010; 49: 5426-45.
25. Koulman A, Lane GA, Harrison SJ, Volmer DA. From differentiating metabolites to biomarkers. Anal Bioanal Chem 2009; 394: 663-70.
26. Kohl M. Standards, databases, and modeling tools in systems biology. Methods Mol Biol 2011; 696: 413-27.
27. Wohlgemuth G, Haldiya PK, Willighagen E, Kind T, Fiehn O. The Chemical Translation Service-a web-based tool to improve standardization of metabolomic reports. Bioinformatics 2010; 26: 2647-8.
28. Oresic M, Lotjonen J, Soininen H. Systems medicine and the integration of bioinformatic tools for the diagnosis of Alzheimer's disease. Genome Med 2010; 2: 83.
29. Kastenmuller G, Romisch-Margl W, Wagele B, Altmaier E, Suhre K. metaP-server: a web-based metabolomics data analysis tool. J Biomed Biotechnol 2011; 2011: 1-7.
30. Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ. Bayesian independent component analysis recovers pathway signatures from blood metabolomics data. J Proteome Res 2012; 11: 4120-31.
31. Yu Z, Zhai G, Singmann P et al. Human serum metabolic profiles are age dependent. Aging Cell 2012; 11: 960-7.
32. Mittelstrass K, Ried JS, Yu Z et al. Discovery of sexual dimorphisms in metabolic and genetic biomarkers. PLoS Genet 2011; 7: e1002215.
33. Illig T, Gieger C, Zhai G et al. A genome-wide perspective of genetic variation in human metabolism. Nat Genet 2010; 42: 137-41.
34. Krug S, Kastenmuller G, Stuckler F et al. The dynamic range of the human metabolome revealed by challenges. FASEB J 2012; 26: 2607-19.
35. Suhre K, Romisch-Margl W, de Angelis MH, Adamski J, Luippold G, Augustin R. Identification of a potential biomarker for FABP4 inhibition: the power of lipidomics in preclinical drug testing. J Biomol Screen 2011; 16: 467-75.
36. Floegel A, Drogan D, Wang-Sattler R et al. Reliability of serum metabolite concentrations over a 4-month period using a targeted metabolomic approach. PLoS ONE 2011; 6: e21103.
37. Adamski J. Genome-wide association studies with metabolomics. Genome Med 2012; 4: 34.
38. Hartman M, Loy EY, Ku CS, Chia KS. Molecular epidemiology and its current clinical use in cancer management. Lancet Oncol 2010; 11: 383-90.
39. Griffiths JR, Stubbs M. Opportunities for studying cancer by metabolomics: preliminary observations on tumors deficient in hypoxia-inducible factor 1. Adv Enzyme Regul 2003; 43: 67-76.
40. Massimo L, Corrias MV, Tonini GP. Why do cancer omics attract clinicians so much? OMICS 2011; 15: 123-4.
41. Trock BJ. Application of metabolomics to prostate cancer. Urol Oncol 2011; 29: 572-81.
42. Bu Q, Huang Y, Yan G, Cen X, Zhao YL. Metabolomics: a revolution for novel cancer marker identification. Comb Chem High Throughput Screening 2012; 15: 266-75.
43. Claudino WM, Goncalves PH, di Leo A, Philip PA, Sarkar FH. Metabolomics in cancer: a bench-to-bedside intersection. Criti Rev Oncol Hematol 2012; 84: 1-7.
44. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-14.
45. Teahan O, Bevan CL, Waxman J, Keun HC. Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol 2011; 43: 1002-9.
46. Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF. Estrogens, enzyme variants, and breast cancer: a risk model. Cancer Epidemiol Biomarkers Prev 2006; 15: 1620-9.
47. Riscuta G, Dumitrescu RG. Nutrigenomics: implications for breast and colon cancer prevention. Methods Mol Biol 2012; 863: 343-58.
48. Simpson NE, Tryndyak VP, Beland FA, Pogribny IP. An in vitro investigation of metabolically sensitive biomarkers in breast cancer progression. Breast Cancer Res Treat 2012; 133: 959-68.
49. Zhang T, Wu X, Yin M et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry. Clin Chim Acta 2012; 413: 861-8.
50. Yoshie T, Nishiumi S, Izumi Y et al. Regulation of the metabolite profile by an APC gene mutation in colorectal cancer. Cancer Sci 2012; 103: 1010-21.
51. Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed 2009; 22: 342-8.
52. Cheng Y, Xie G, Chen T et al. Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res 2012; 11: 1354-63.
53. Leichtle AB, Nuoffer JM, Ceglarek U et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012; 8: 643-53.
54. Nishiumi S, Kobayashi T, Ikeda A et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE 2012; 7: e40459.
55. Denkert C, Budczies J, Weichert W et al. Metabolite profiling of human colon carcinoma-deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008; 7: 72.
56. Clyne M. Kidney cancer: metabolomics for targeted therapy. Nat Rev Urol 2012; 9: 355.
57. Hori S, Nishiumi S, Kobayashi K et al. A metabolomic approach to lung cancer. Lung Cancer 2011; 74: 284-92.
58. Hyndman ME, Mullins JK, Bivalacqua TJ. Metabolomics and bladder cancer. Urol Oncol 2011; 29: 558-61.
59. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, Gunther UL. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS ONE 2009; 4: e4251.
60. Zanuy M, Ramos-Montoya A, Villacanas O et al. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics 2012; 8: 454-64.
61. Weljie AM, Jirik FR. Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect. Int J Biochem Cell Biol 2010; 43: 981-9.
62. Alcarraz-Vizan G, Boren J, Lee WN, Cascante M. Histone deacetylase inhibition results in a common metabolic profile associated with HT29 differentiation. Metabolomics 2010; 6: 229-37.
63. Williams SN, Anthony ML, Brindle KM. Induction of apoptosis in two mammalian cell lines results in increased levels of fructose-1, 6-bisphosphate and CDP-choline as determined by 31P MRS. Magn Reson Med 1998; 40: 411-20.
64. Ronen SM, DiStefano F, McCoy CL et al. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer 1999; 80: 1035-41.
65. Luciani AM, Grande S, Palma A et al. Characterization of 1H NMR detectable mobile lipids in cells from human adenocarcinomas. FEBS J 2009; 276: 1333-46.
66. Milkevitch M, Shim H, Pilatus U et al. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim Biophys Acta 2005; 1734: 1-12.
67. Rainaldi G, Romano R, Indovina P et al. Metabolomics using 1H-NMR of apoptosis and Necrosis in HL60 leukemia cells: differences between the two types of cell death and independence from the stimulus of apoptosis used. Radiat Res 2008; 169: 170-80.
68. Egawa-Takata T, Endo H, Fujita M et al. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. Cancer Sci 2010; 101: 2171-8.
69. Suhre K. Genome-Wide Association Studies with Metabolomics. Suhre K, ed. Genetics Meets Metabolomics. New York: Springer, 2012; 265-79.
70. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 2005; 258: 479-517.
71. Laxman B, Hall DE, Bhojani MS et al. Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 2002; 99: 16551-5.
72. Kim YE, Chen J, Langen R, Chan JR. Monitoring apoptosis and neuronal degeneration by real-time detection of phosphatidylserine externalization using a polarity-sensitive indicator of viability and apoptosis. Nat Protoc 2010; 5: 1396-405.
73. Zhao M. Molecular recognition mechanisms for detecting cell death in vivo. Curr Pharm Biotechnol 2010; 11: 693-700.
74. Okamoto-Kubo S, Nishio K, Heike Y, Yoshida M, Ohmori T, Saijo N. Apoptosis induced by etoposide in small-cell lung cancer cell lines. Cancer Chemother Pharmacol 1994; 33: 385-90.
75. Osaki M, Tatebe S, Goto A, Hayashi H, Oshimura M, Ito H. 5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene. Apoptosis 1997; 2: 221-6.
76. Halama A, Moller G, Adamski J. Metabolic signatures in apoptotic human cancer cell lines. OMICS 2011; 15: 325-35.
77. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
78. Ferrannini E, Natali A, Camastra S et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance. Diabetes 2012; 62: 1730-7.
79. Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. Int J Proteomics 2011; 2011: 343582.
80. Tukiainen T, Tynkkynen T, Makinen VP et al. A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun 2008; 375: 356-61.
81. Wang-Sattler R, Yu Z, Herder C et al. Novel biomarkers for pre-diabetes identified by metabolomics. Mol Syst Biol 2012; 8: 615.
82. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009; 15: 431-40.
83. Wang-Sattler R, Yu Y, Mittelstrass K et al. Metabolic profiling reveals distinct variations linked to nicotine consumption in humans-First results from the KORA study. PLoS ONE 2008; 3: e3863.
84. Altmaier E, Kastenmüller G, Römisch-Margl W et al. Variation in the human lipidome associated with coffee consumption as revealed by quantitative targeted metabolomics. Mol Nutr Food Res 2009; 53: 1357-65.
85. Rezzi S, Martin FP, Alonso C et al. Metabotyping of biofluids reveals stress-based differences in gut permeability in healthy individuals. J Proteome Res 2009; 8: 4799-809.
86. Cuperlovic-Culf M, Barnett DA, Culf AS, Chute I. Cell culture metabolomics: applications and future directions. Drug Discovery Today 2010; 15: 610-21.
87. Weinberg RA. The Biology of Cancer. New York: Garland Science, 2007.
88. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005; 26: 263-70.
89. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004; 4: 551-61.
90. Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem 2003; 49: 1797-817.
91. de Jong RS, Mulder NH, Dijksterhuis D, de Vries EG. Review of current clinical experience with prolonged (oral) etoposide in cancer treatment. Anticancer Res 1995; 15: 2319-30.
92. IMPACT. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939-44.
93. Warskulat U, Borsch E, Reinehr R et al. Taurine deficiency and apoptosis: findings from the taurine transporter knockout mouse. Arch Biochem Biophys 2007; 462: 202-9.
94. Takatani T, Takahashi K, Uozumi Y et al. Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. Am J Physiol Cell Physiol 2004; 287: C949-53.
95. Vander Heiden MG, Locasale JW, Swanson KD et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 2010; 329: 1492-9.
96. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 2003; 23: 1149-54.
97. Mazurek S. Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours. Ernst Schering Found Symp Proc 2007; 4: 99-124.
98. Jahns-Streubel G, Reuter C, Auf der Landwehr U et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 1997; 90: 1968-76.
99. Brunet J, Vazquez-Martin A, Colomer R, Grana-Suarez B, Martin-Castillo B, Menendez JA. BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 2008; 47: 157-63.
100. Fleming H, Blumenthal R, Gurpide E. Rapid changes in specific estrogen binding elicited by cGMP or cAMP in cytosol from human endometrial cells. Proc Natl Acad Sci USA 1983; 80: 2486-90.
101. Warrington NM, Gianino SM, Jackson E et al. Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. Cancer Res 2010; 70: 5717-27.
102. Mazurek S, Hugo F, Failing K, Eigenbrodt E. Studies on associations of glycolytic and glutaminolytic enzymes in MCF-7 cells: role of P36. J Cell Physiol 1996; 167: 238-50.
103. Adams S, Braidy N, Bessesde A et al. The kynurenine pathway in brain tumor pathogenesis. Cancer Res 2012; 72: 5649-57.
104. Crott J, Thomas P, Fenech M. Normal human lymphocytes exhibit a wide range of methionine-dependency which is related to altered cell division but not micronucleus frequency. Mutagenesis 2001; 16: 317-22.